TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03476174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Subjects will receive 200 mg pembrolizumab every 3 weeks for two cycles. Cycle length is 21 days (i.e., 3 weeks). On the last day of Cycle 2 (+/- 3 days), disease status will be assessed via imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Following the pembrolizumab treatment, HD IL-2 treatment will commence. After completing the 2 cycles of pembrolizumab, High Dose Interleukin-2 (HD IL-2) will be administered. This will require a hospital stay of at least 5 days for each treatment cycle. Established guidelines will be followed for safely administering HD-IL-2 and managing toxicities from this treatment. Two treatment cycles will be administered, Cycle 2 being separated from Cycle 1 by approximately 9 days after completion (assuming subject has recovered from Cycle 1 adequately to proceed with Cycle 2). Four weeks after completion of the 2 cycles (called a course of HD IL-2 therapy), disease status will be monitored via CT of the chest and abdomen/pelvis using revised RECIST guidelines
Study: NCT03863457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoroglutamine [18F]F-GLN
Description: Evaluate the kinetics and biodistribution of \[18F\]F-GLN in primary and metastatic breast cancer.
Study: NCT03531528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
Study: NCT03205735

Intervention type: DIAGNOSTIC_TEST
Intervention: lymphocyte DPD dosage
Description: lymphocyte DPD dosage in peripheral blood

Intervention type: DIAGNOSTIC_TEST
Intervention: lymphocyte DPD dosage
Description: lymphocyte DPD dosage in peripheral blood
Study: NCT06493656

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided glenohumeral space isolated corticosteroid injection
Description: Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection
Description: Using a 21-gauge spinal needle, the predefined steroid solution with additional 15 mL of normal saline was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1mL of Triamcinolone (40mg/1mL) Injectable Solution
Description: 1mL of Triamcinolone 40mg/1mL solution was included in the injection/hydrodilatation regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mL of Triamcinolone (40mg/1mL) Injectable Solution
Description: 1mL of Triamcinolone 40mg/1mL solution was included in the injection/hydrodilatation regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mL of Lidocaine 1% Solution Injectable Solution
Description: 4mL of 1% Lidocaine solution was included in the injection/hydrodilatation regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mL of Lidocaine 1% Solution Injectable Solution
Description: 4mL of 1% Lidocaine solution was included in the injection/hydrodilatation regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15mL of Normal Saline
Description: 15mL of 1% Lidocaine solution was included in the hydrodilatation regimen.
Study: NCT02046005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRE-RA
Description: Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRE-RA Plus
Description: Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information. In addition, participants in this arm receive education from a health educator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Rheumatoid Arthritis Education
Description: Participants will receive general information about signs and symptoms of rheumatoid arthritis.
Study: NCT02956447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 112-121
Description: 0.313 ug/kg - 2 ug/kg IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 112-121
Description: 0.313 ug/kg - 2 ug/kg IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: 0.075 ug/kg IV
Study: NCT03168737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine F 18-fluoroazomycin Arabinoside
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine F 18-fluoroazomycin Arabinoside
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT scan
Study: NCT04230512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pump prototype
Description: Effects of pump function on gait

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pump prototype
Description: Effects of pump function on gait
Study: NCT03164655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil
Description: Oxaliplatin 100 mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5 mg/kg infusion in 30 minutes, Panitumumab 6 mg/kg, Irinotecan 180 mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400 mg/m² infusion in 2 hours, 5-Fluorouracil 2400 mg/m² infusion continuous in 46h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil
Description: Oxaliplatin 100 mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5 mg/kg infusion in 30 minutes, Panitumumab 6 mg/kg, Irinotecan 180 mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400 mg/m² infusion in 2 hours, 5-Fluorouracil 2400 mg/m² infusion continuous in 46h
Study: NCT03813147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecally and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given intrathecally
Study: NCT03664310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FSET Anxiety and Sleep Treatment
Description: Computerized anxiety and insomnia intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Physical health control
Study: NCT00773578

Intervention type: DEVICE
Intervention: Measurement of exhaled nitric oxide (eNO)
Description: Chemiluminescence NO analyzer Measurement of lung function (spirometry)

Intervention type: DEVICE
Intervention: Measurement of exhaled nitric oxide (eNO)
Description: Chemiluminescence NO analyzer Measurement of lung function (spirometry)

Intervention type: DEVICE
Intervention: Measurement of biomarkers of nasal inflammation
Description: Nasal lavage

Intervention type: DEVICE
Intervention: Measurement of biomarkers of nasal inflammation
Description: Nasal lavage
Study: NCT02345889

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy with EndoCuff™
Description: colonoscopy performed with an EndoCuff™ device at the tip of a standard colonoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FUSE® Colonoscopy
Description: colonoscopy performed with the FUSE® (full spectrum endoscopy) system
Study: NCT00004221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study: NCT01219595

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetened, dried cranberries
Description: Women in Arm 1 will consume one serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetened, dried cranberries
Description: Women in Arm 1 will consume one serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetened, dried cranberries
Description: Women in Arm 1 will consume one serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strawberry Fruit Pieces
Description: 1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
Study: NCT02345889

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy with EndoRings™
Description: colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Current standard of care colonoscopy
Study: NCT00727844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Start Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed Start Linezolid
Study: NCT05492487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirena
Description: Mirena Intrauterine System (Mirena-IUS) is a levonorgestrel-releasing intrauterine system. Mirena consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir (hormone elastomer core) around the vertical stem. The reservoir consists of a white or almost white cylinder, made of a mixture of levonorgestrel and silicone (polydimethylsiloxane), containing a total of 52 mg levonorgestrel. Mirena is approved for intrauterine contraception and in 2009 to treat heavy periods for women who choose intrauterine contraception. Mirena is often used off-label for the treatment of endometrial hyperplasia. Levonorgestrel is a progestogen used in a variety of contraceptive products. Low doses of levonorgestrel can be administered into the uterine cavity with the Mirena intrauterine delivery system. Mirena has mainly local progestogenic effects in the uterine cavity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megace
Description: Megestrol acetate (Megace) is a synthetic derivative of the natural occurring steroid hormone, progesterone. It is licensed for the treatment of anorexia, cachexia or unexplained weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS) and palliative treatment of advanced breast or endometrial cancer. Megace is often used off-label for the treatment of endometrial hyperplasia. While the precise mechanism by which Megace produces its antineoplastic effects against endometrial carcinoma and endometrial hyperplasia is unknown at the present time, inhibition of pituitary gonadotrophin production and resultant decrease in estrogen secretion may be factors. There is evidence to suggest a local effect as a result of the marked changes brought about by the direct instillation of progestational agents into the endometrial cavity.
Study: NCT05108142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: fresh, hot pasta and re-heated pasta

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: fresh, hot pasta and re-heated pasta
Study: NCT01219595

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strawberry Fruit Pieces
Description: 1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetened, dried cranberries
Description: 1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetened, dried cranberries
Description: 1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetened, dried cranberries
Description: 1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetened, dried cranberries
Description: 1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetened, dried cranberries
Description: 1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
Study: NCT01845168

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-alert
Description: A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in kombination, Adenosine-diphosphate-inhibitor (ADP-inhibitor), blood-thinning medicine, Selective serotonin reuptake-inhibitor (SSRI) and steroids

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A computer alerts which pops up when the GP presribes NSAID/ASA to a patient with risk-factors
Description: A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in combination, ADP-inhibitor, bloodthinning medicine, SSRI, and steroids

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer-alert
Study: NCT04450407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC
Study: NCT01219595

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetened, dried cranberries
Description: 1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strawberry Fruit Pieces
Description: 1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strawberry Fruit Pieces
Description: 1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Subjects in the non-UTI susceptible group will have one visit where one vaginal and one rectal swab will be collected.
Study: NCT04035655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coma Recovery Scale - revised
Description: Assessment of the level of consciousness by the dedicated Coma Recovery Scale - Revised, current gold-standard in consciousness level assessment.~Assessment before and after the tDCS session (immediately before and after the electrophysiological assessment, see below).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrophysiological recordings
Description: The electrophysiological assessment consisted of:~* a 5 minutes resting state high-density EEG recording~* a approximately 6 minutes auditory oddball paradigm These two procedures were administered immediately before and after the tDCS session
Study: NCT04450407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study: NCT03467763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Extended Release Oral Tablet
Description: Metformin hydrochloride extended release tablets in dosages of 250 mg, 500 mg, 750 mg, and 1,000 mg. Individual encapsulations of metformin will contain dosages of 250 mg or 500 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule
Study: NCT01505738

Intervention type: OTHER
Intervention: bacterial samples
Description: bacterial samples taken
Study: NCT01768975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLT1177 Gel
Description: 4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
Study: NCT00382525

Intervention type: DEVICE
Intervention: Cardiac Rhythm Management device
Study: NCT00855205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15
Study: NCT00101075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT00519233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-1C4D4
Description: IV
Study: NCT03721835

Intervention type: DEVICE
Group type: OTHER
Intervention: CONQUEST FN Femoral Neck Fracture System
Description: Fracture fixation device consisting of a single plate and three screws
Study: NCT00228319

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Ascorbic Acid
Description: 4 grams per day for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Six cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Six cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ascorbate
Description: Intravenous infusion at 0.5 gram/min twice weekly over 1-2 hours at a dose to achieve levels of 400 mg/dl for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Mixed natural Carotenoids with Vitamin A
Description: Capsule containing mixed carotenoids and vitamin A. Participant to take 1 daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 500 IU per capsule and participant to take 1 capsule daily for 12 months
Study: NCT02211690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir 50 mg (one tablet daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine-tenofovir 300/200 mg (one tablet daily)
Study: NCT02961322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lobo-isthmectomy assisted robot
Study: NCT02850016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous Infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Intravenous Infusion of Romidepsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Intravenous Infusion of Romidepsin
Study: NCT00574210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablets administered twice per day
Study: NCT03247491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
Study: NCT02499146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg , orally once daily (continuously)
Study: NCT03090724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: 100 mg of BIA 5-453 (combination of two 50 mg capsules); Oral, once-daily (QD), in the morning in fasting conditions
Study: NCT02720289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-based social learning class
Description: Brief child passenger safety lecture by a child passenger safety technician and viewing of a car seat video.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional didactic class
Description: Child passenger safety lecture by a child passenger safety technician.
Study: NCT01551719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implemented procedure
Description: Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection.